Abbott Laboratories (ABT) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Abbott Laboratories (ABT) advanced +1.88% to $104.57 as options desks priced 56% call premium vs. 44% put protection around the $102 max-pain magnet. Solid 56% profit margin (12% return on capital), mixed timing at 28x P/E—hold if owned, no rush to chase.
Abbott Laboratories has seen a mixed share price record in recent years, which raises a straightforward question for anyone following the stock: Are the cash flows that Abbott can generate over time enough to justify whe
Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Human Papillomavirus (HPV) Genotyping Panels Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global human papillomavirus (HPV) genotyping pan
Some of the stock trades made by members of the House and Senate might surprise you.
Boost ROI with home INR analyzers, recurring consumable sales, distribution partnerships, and local assembly to reduce tariff exposure and testing costs.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Point-of-Care Internatio
Dexcom, known for its G-series of diabetes wearables, topped September-quarter expectations late Thursday, leading to a guidance hike.
New York-listed Perrigo said the divesture follows a strategic review, concluding a sale is the “best path forward for the business and its stakeholders”.
AbbVie built its empire on a single blockbuster drug, then watched biosimilars gut it almost overnight. Whether the replacement pipeline saved investors or left them holding the bag depends on when they bought and whethe
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "South & Central America Point of Care Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis" has been added to ResearchAndMa
For questions about this article or underlying research, email help@trefis.com.
Abbott (NYSE: ABT), the global healthcare leader, announced today it has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ABT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ABT. Explore sector supply chains on /butterfly.
Why ABT Stock advanced +1.88% Today — RQD Quant Desk Flash. Solid 56% profit margin (12% return on capital), mixed timing at 28x P/E—hold if owned, no rush to chase.